CAMBRIDGE, Mass. – Beam Therapeutics Inc. (NASDAQ:BEAM) introduced at the moment that the U.S. Meals and Drug Administration has cleared its investigational new drug utility for BEAM-304, a remedy for phenylketonuria. The inventory rose to $32.48 following the announcement, persevering with a powerful efficiency that has delivered a 91% return over the previous 12 months. With a market capitalization of $3.23 billion, the biotech firm’s shares stay extremely unstable with a beta of two.2.
The corporate plans to advance BEAM-304 utilizing a improvement method by which a number of mutation-specific base editors are developed inside a single scientific program utilizing in vivo supply, in accordance with a press launch assertion.
Phenylketonuria is a uncommon inherited metabolic dysfunction that leads to poisonous accumulation of phenylalanine, resulting in neurologic and neurocognitive impairments. The illness impacts roughly 20,000 individuals within the U.S. and requires lifelong dietary administration.In accordance with InvestingPro information, Beam maintains a powerful steadiness sheet with more money than debt and a present ratio of 16.99, offering substantial monetary runway for scientific improvement. Whereas the corporate stays unprofitable with analysts not anticipating profitability this 12 months, its sturdy liquidity place helps ongoing analysis packages. Buyers can entry complete evaluation by InvestingPro’s Professional Analysis Report, certainly one of 1,400+ accessible for US equities, together with 9 further ProTips for BEAM.
BEAM-304 makes use of base enhancing expertise and lipid nanoparticle supply to appropriate mutations within the phenylalanine hydroxylase gene that trigger PKU. The remedy goals to revive PAH enzyme exercise to scale back poisonous phenylalanine to really useful guideline ranges of 360 µmol/L or beneath.
Preclinical information confirmed that BEAM-304 normalized plasma phenylalanine ranges in PKU mouse fashions at clinically related doses with on-target enhancing within the liver. Up to date preclinical information will likely be offered on the FASEB Genome Engineering: Analysis and Functions Convention going down July 6-9, 2026, in Porto, Portugal.
The deliberate Section 1/2 trial will initially consider security, tolerability, discount of blood phenylalanine ranges and food plan liberalization in PKU sufferers with the R408W mutation, adopted by a base editor designed to deal with a second mutation.
Preliminary scientific improvement will concentrate on base editors addressing the 2 most prevalent variants present in almost half of sufferers with PKU within the U.S., with ongoing analysis efforts to deal with further pathogenic mutations.
BEAM-304 is delivered through intravenous infusion. There are at present no accredited healing therapies for PKU, with current remedy choices requiring lifelong dietary restriction and power illness administration.
In different latest information, Beam Therapeutics Inc. reported its first-quarter 2026 outcomes, highlighting progress in its BEAM-302 program for alpha-1 antitrypsin deficiency. The corporate introduced that BEAM-302 is advancing towards pivotal improvement, with up to date Section 1/2 information exhibiting promising outcomes, together with speedy and sturdy will increase in whole and practical AAT. Moreover, Beam Therapeutics has chosen 60 mg because the optimum organic dose for this remedy. H.C. Wainwright reiterated a Purchase ranking for Beam Therapeutics, sustaining an $80.00 worth goal, citing the corporate’s progress in scientific and regulatory milestones as central to its funding thesis.
Beam Therapeutics additionally offered scientific information from its BEAM-302 Section 1/2 trial on the American Thoracic Society Worldwide Convention, showcasing security outcomes, efficacy sturdiness, and a discount in human neutrophil elastase exercise. Moreover, the corporate introduced upcoming shows on the European Hematology Affiliation 2026 Congress, the place it should share up to date biomarker information from its BEACON Section 1/2 scientific trial for sickle cell illness. The trial information for risto-cel, an investigational remedy for sickle cell illness, was just lately revealed in The New England Journal of Drugs, based mostly on follow-ups from 31 sufferers. These developments replicate Beam Therapeutics’ ongoing efforts in advancing its genetic illness and hematology packages.
This text was generated with the help of AI and reviewed by an editor. For extra info see our T&C.
